lakosamid +pharma 100mg potahovaná tableta
+pharma arzneimittel gmbh, graz array - 16489 lakosamid - potahovaná tableta - 100mg - lakosamid
lakosamid +pharma 150mg potahovaná tableta
+pharma arzneimittel gmbh, graz array - 16489 lakosamid - potahovaná tableta - 150mg - lakosamid
lakosamid +pharma 200mg potahovaná tableta
+pharma arzneimittel gmbh, graz array - 16489 lakosamid - potahovaná tableta - 200mg - lakosamid
lakosamid +pharma 50mg potahovaná tableta
+pharma arzneimittel gmbh, graz array - 16489 lakosamid - potahovaná tableta - 50mg - lakosamid
sufentanil torrex 5mcg/ml injekční roztok
chiesi pharmaceuticals gmbh, vídeň array - 11995 sufentanil-citrÁt - injekční roztok - 5mcg/ml - sufentanil
sufentanil torrex 50mcg/ml injekční roztok
chiesi pharmaceuticals gmbh, vídeň array - 11995 sufentanil-citrÁt - injekční roztok - 50mcg/ml - sufentanil
fentanyl torrex 50mcg/ml injekční roztok
chiesi pharmaceuticals gmbh, vídeň array - 612 fentanyl-citrÁt - injekční roztok - 50mcg/ml - fentanyl
solifenacin aristo 10mg potahovaná tableta
aristo pharma gmbh, berlin array - 17227 solifenacin-sukcinÁt - potahovaná tableta - 10mg - solifenacin
solifenacin aristo 5mg potahovaná tableta
aristo pharma gmbh, berlin array - 17227 solifenacin-sukcinÁt - potahovaná tableta - 5mg - solifenacin
celsunax
pinax pharma gmbh - joflupan (123i) - radionuclide imaging; dementia; movement disorders - diagnostické radiofarmaka - tento léčivý přípravek je určen pouze pro diagnostické účely. celsunax is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum:in adult patients with clinically uncertain parkinsonian syndromes, for example those with early symptoms, in order to help differentiate essential tremor from parkinsonian syndromes related to idiopathic parkinson’s disease, multiple system atrophy and progressive supranuclear palsy. celsunax is unable to discriminate between parkinson's disease, multiple system atrophy and progressive supranuclear palsy. u dospělých pacientů, pomoci odlišit pravděpodobné demence s lewyho tělísky od alzheimerovy choroby. celsunax is unable to discriminate between dementia with lewy bodies and parkinson’s disease dementia.